Medivir AB Acquires Preclinical Antiviral Programs Including Hepatitis C and Prodrug Technologies

Published: Sep 05, 2012

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB) is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people’s lives. Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir’s hepatitis C platform and know how.

Back to news